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We have identified a novel family of five 3V co-terminal transcripts in murine cytomegalovirus (MCMV) arranged in a tail-to-tail
orientation with respect to the MCMV glycoprotein H (gH) gene M75. They share the same exon 2 sequence but possess different exon 1
sequences. Two of these spliced transcripts (M73) encode the MCMV homolog of glycoprotein N (gN) entirely within exon 1. Two other
transcripts designated M73.5 encode a previously described virion glycoprotein gp24 that shares its first 20 amino acids with gN, but which
has another 64 amino acids encoded within exon 2. The fifth transcript, designated m60, has an 80-bp exon 1 near the MCMVoriLyt region
10.8 kb upstream of exon 2. Both MCMV M73.5 and m60 encode type II glycoproteins expressed at the cell surface. Their shared exon 2
coding sequences likely represent the highly conserved region of an as yet unidentified betaherpesvirus-specific glycoprotein species.
D 2004 Elsevier Inc. All rights reserved.
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polymorphismIntroduction
Murine cytomegalovirus (MCMV) is a member of the
Betaherpesvirinae subfamily of Herpesviridae. Character-
istic features of betaherpesviruses include slow replication
cycle, restricted host range, and the establishment of latency
in secretory glands, lymphoreticular cells, kidney, and other0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.08.015
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Australia, Nedlands, WA 6509, Australia.tissues (Mocarski, 1996). This subfamily includes three
human viruses, including human CMV (HCMV), human
herpesvirus-6 (HHV6), and human herpesvirus-7 (HHV7).
Many animal species also harbor betaherpesviruses. Apart
from MCMV, other representative animal betaherpesviruses
include chimpanzee CMV (CCMV), rhesus CMV
(RhCMV), rat CMV (RCMV), guinea pig CMV (GPCMV),
and Tupaia herpesvirus of tree shrews (THV). Except for
GPCMV, which has only been partly sequenced (Brady and
Schleiss, 1996), all of these betaherpesviruses have been
fully sequenced (Bahr and Darai, 2001; Chee et al., 1990;
Davison et al., 2003; Gompels et al., 1995; Hansen et al.,
2003; Megaw et al., 1998; Rawlinson et al., 1996; Vink et al.,
2000).04) 234–250
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meant that many aspects of the pathogenesis of HCMV
infection of humans cannot be directly investigated in
animal models. Thus, the many parallels in HCMV and
MCMV pathogenesis in their respective hosts (Staczek,
1990; Sweet, 1999) and the similarities in their molecular
makeup have led to a widespread usage of MCMV as a
model system for HCMV pathogenesis. The MCMV
genome, which is 230-kb long, has been predicted to
encode approximately 170 open reading frames (ORFs)
(Rawlinson et al., 1996). In that analysis, a total of 64 genes
were identified as having the potential to encode glyco-
proteins based on similarities to other herpesviruses or the
presence of potential transmembrane regions and N-linked
glycosylation sites within predicted ORFs.
The main structural virion glycoproteins of cytomegalo-
virus characterized to date include those forming the
glycoprotein complexes gCI, gCII, and gCIII first identified
in HCMV (Gretch et al., 1988). In HCMV, the gCI complex
has been found to be a homodimeric complex (gB/gpUL55)
involved in fusion. The gCII complex is a dimer comprising
gM and gN (gpUL100 and gpUL73, respectively) (Mach et
al., 2000) and possesses heparin-binding functions (Kari and
Gehrz, 1992, 1993). The final complex gCIII has been
shown to be a heterotrimer comprising gH (gpUL75), gL
(gpUL115), and gO (gpUL74) (Huber and Compton, 1998).
The gCIII complex, like gCI, is also involved in fusion with
the host cell membrane. The UL33-encoded G-protein-
coupled receptor homologue GPR33 has also been found to
be a structural component of HCMV (Fraile-Ramos et al.,
2002; Margulies et al., 1996). Cytomegaloviruses also
encode many other glycoproteins, though most of these
are only expressed in infected cells and many are involved
in perturbing the host’s immune response through their
immunomodulatory functions (Mocarski, 2002; Tortorella
et al., 2000).
Despite the MCMV sequence having been determined for
some time now, only a few structural virion glycoproteins
have been characterized thus far. These include gB (Loh,
1991; Loh et al., 1988; Rapp et al., 1992; Xu et al., 1996), gH
(Loh and Qualtiere, 1988; Rapp et al., 1994, 1993; Xu et al.,
1992), gL (Xu et al., 1994), and gM (Li et al., 1995; Scalzo et
al., 1995). Another virion glycoprotein designated gp24 was
identified using the neutralizing monoclonal antibody (MAb)
6A1.21A (Loh, 1989). However, a HCMV homolog to gp24
has not yet been described.
In this study, we report on the identification and
characterization of the M73/M73.5 family of transcripts
and their gene products. During the screening of a MCMV
cDNA library with a polyclonal antiserum to MCMV, we
identified a cDNA clone, TS9, which represented a novel
spliced transcript present in the MCMV genome. It is
arranged in a tail-to-tail arrangement with respect to the
M75 (gH) ORF and consists of two exons. Analysis by
immunofluorescence, immunoprecipitation, and Western
blotting has shown that the protein encoded by TS9resembled the previously described virion glycoprotein
gp24. Final confirmation of its identity was provided by
the sequencing of tryptic peptides derived from gp24 that
was immunoprecipitated from MCMV-infected cells by
MAb 6A1.21A. Database analysis indicates that this
glycoprotein is conserved in all betaherpesviruses. Further
analyses of MCMV transcripts in this region revealed
additional spliced transcripts that were 3V co-terminal with
the novel M73.5 mRNA. Firstly, the gene encoding MCMV
gN (M73) is a spliced transcript with the gN ORF residing
entirely within the first exon, and it also shares its second
exon with M73.5. Secondly, longer versions of M73 and
M73.5 transcripts with extended 5V ends also exist. Finally,
an additional 3V co-terminal spliced transcript of this gene
family was identified, which has its exon 1 located nearly
10.8 kb upstream near the MCMV OriLyt region, but which
shares the same exon 2 with both M73 and M73.5,
indicating a complex genomic pattern of transcription in
this region.Results
Isolation of the M73.5 sequence from an MCMV cDNA
library
Polyclonal hyperimmune antiserum to MCMV was used
to screen a Egt11 cDNA library prepared from mRNAs
isolated from MCMV-infected mouse embryo fibroblasts
(MEFs) at 24 h after infection (Dallas et al., 1994). An insert
from a positive clone (initially designated TS9) was
amplified by PCR (polymerase chain reaction) and subcl-
oned into pGEM11-Zf(+). A comparison of the 420-bp
cDNA sequence with the complete sequence of the Smith
strain of MCMV (Rawlinson et al., 1996) indicated that the
transcript encoding this cDNA is spliced (Fig. 1). The first
162 nucleotides of the transcript represent nucleotides
103,999–104,160 of the published MCMV sequence, a
region that encodes MCMV M73 (gN), and the following
215 nucleotides represent nucleotides 105,879–106,093
followed by a 43-bp poly(A) tail. The transcript has a
combined stop/polyadenylation signal at nucleotides
106,068–106,073. This transcript contains a 252-bp open-
reading frame (ORF) encoding a putative protein of 84
amino acid residues with a predicted molecular weight of
8.8 kDa (Fig. 1). A potential N-linked glycosylation site
(NAT) is located at amino acid residues 74–76. Interest-
ingly, the first 20 amino acid residues of this protein are
shared with the M73-encoded gN molecule, and therefore
this novel glycoprotein is designated gpM73.5. Several
features suggest gpM73.5 is a type II integral membrane
protein. First, it lacks a hydrophobic N-terminal signal
peptide sequence, and second, a potential N-linked glyco-
sylation site (NAT) is present in the C-terminal domain,
downstream of a potential transmembrane region spanning
amino acid residues 36–53 (VIMVAMMLVLYRAIVGF).
Fig. 1. The DNA and deduced amino acid sequence of the M73.5 cDNA.
The first G nucleotide after the splice site is identified by an arrow. The first
20 amino acids of the M73.5 protein sequence shared with M73 are shown
in bold. The combined stop codon and polyadenylation signal is indicated
by the double underline, and the putative N-linked glycosylation site (NAT)
is indicated by a dotted underline. The amino acid sequences of two
purified tryptic digest peptides derived from gp24 immunoprecipitated from
MCMV-infected fibroblasts with MAb 6A1.21A are underlined.
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Northern blot analyses
To investigate the size and kinetics of expression of the
transcript from which the M73.5 cDNA was derived,
Northern blot analysis was undertaken using total RNA
isolated from uninfected MEFs and MCMV-infected MEFs
at 4, 8, 16, 20, or 24 h (hr) post-infection (p.i.). RNA was
also extracted from MEFs infected with MCMV in the
presence of 250 Ag/mL of PAA (phosphonoacetic acid) at
24 h p.i. RNA was run on 1.4% agarose gels following
glyoxylation of samples. The Northern blot was sequentially
probed with the full-length M73.5 cDNA probe, and with a
series of probes specific for M72, M73, m74, exon 2 of the
M73.5 ORF, and M75. The location of these probes in the
MCMV genome is depicted in Fig. 2A. The blot was also
probed with a M55 (gB) probe, which is a known late gene,
and finally a mouse b-actin probe, to verify equivalent RNA
loading.
Fig. 2B shows that the M73.5 cDNA probe detects a
0.85-kb transcript at 4 h p.i. (lane 2). At 8 h p.i., 0.75–0.9
and 1.1–1.2-kb transcripts were detected (lane 3). At 16 h
p.i., the level of expression of these transcripts increased and
additional transcripts were detected. These included
mRNAs with discrete sizes of 3.8, 3.1, 2.6, 2.1, and 1.7
kb, and a transcript (or transcripts) ranging in size from 0.45
to 0.6 kb (lane 4). At later time points, all of these transcripts
were still present, and there was also abundant expression of
the 0.75–0.9- and 0.45–0.6-kb transcripts, as well as asmaller 0.3–0.4-kb transcript (lanes 5 and 6). Both the 0.75–
0.9- and 1.1–1.2-kb transcripts were weakly detected in cells
cultured in the presence of PAA (lane 7), suggesting that
these transcripts may be leaky late transcripts with predom-
inant expression at late time points. When the M72-specific
probe was used, only the 3.8-, 2.6-, and 1.7-kb transcripts
were detected (Fig. 2C). Use of a probe specific for the M73
ORF presented a pattern of transcription essentially identical
to that with the full-length M73.5 cDNA probe (Fig. 2D),
with the exception that the 0.3–0.4-kb transcript was absent.
Other than the presence of a 3.1-kb transcript at 20 h p.i., a
similar pattern of expression to that observed for the M72
probe was obtained with the m74-specific probe (Fig. 2E).
The M73.5 exon-2-specific probe yielded an expression
pattern essentially identical to that obtained with the full-
lengthM73.5 cDNA probe (Fig. 2F), with the exception that
the 1.7- and 2.6-kb transcripts were not detected. Using a
probe specific for M75 (gH), only the 3.8-kb band was
detected (data not shown). Probing of the blot with a 907-bp
probe for M55 (gB), which is a true late gene, revealed
increasing expression commencing from 16 h post-infec-
tion, and transcription was completely blocked in the
presence of PAA (Fig. 2G). Finally, probing of the blot
with a mouse h-actin probe confirms that essentially equal
amounts of RNA sample were loaded in each lane (Fig. 2H).
These data indicate that the 0.45–0.6-, 0.75–0.9-, and
1.1–1.2-kb transcripts are likely to be spliced, with introns
spanning the m74 ORF and exons present in the M73 region
(exon 1) as well as the intergenic region between m74 and
M75 (exon 2). The 1.7- and 2.6-kb transcripts span the
region from M72 to m74, and the 3.8-kb transcript spans the
region from M72 to M75. Lastly, the 3.1-kb transcript spans
the region covered by the M73.5 cDNA, m74, M73.5 exon
2, and M73 ORF probes.
RACE-PCR and RT-PCR analyses
To gain further insights into the genomic organization of
the abundantly expressed spliced transcripts, we initially
performed 5V-RACE (rapid amplification of cDNA ends)
PCR to define the 5V ends of these transcripts using primers
specific for the exon 2 sequence of the M73.5 cDNA and
total RNA isolated at 24 h post-infection. The M73.5
specific primer TS9-Not1-Rev (see Table 1) was used for
priming reverse transcription and then the TS91 and TS94
primers were used for primary and nested PCR, respectively.
Fig. 3A (lane 2) shows that 2 major 5V-RACE PCR products
approximately 0.3 and 0.65 kb in size were obtained, with a
faint band also present at approximately 0.2 kb. These
products were gel-purified, cloned into pGEM-T, and their
nucleotide sequences were determined. Nucleotide sequen-
ces of uncloned, gel-purified PCR products were also
determined.
The 300-bp fragment represents part of a spliced
transcript in which the first exon spans nucleotides
103,985–104,160 and the exon 2 fragment spans nucleo-
tides 105,879–106,093, terminating at the binding site for
Fig. 2. Schematic summary of spliced transcripts spanning the HindIII D/C junction and Northern blot analysis of transcripts expressed from this genomic
region. (A) Map of the HindIII restriction enzyme fragments of the K181 strain of MCMV with an expanded view of the HindIII D/C fragment junction shown
below. The gray bars represent DNA probes used for probing Northern blots. Summarized at the bottom are the spliced transcripts characterized in this study.
The longer versions of theM73 andM73.5 transcripts are represented by the open boxes at the 5V-ends of these transcripts. All nucleotide coordinates are given
relative to the published Smith MCMV strain sequence (Rawlinson et al., 1996). (B–H) Northern blot of RNA isolated from uninfected MEF (lane 1), or MEF
infected with MCMV for 4 h (lane 2), 8 h (lane 3), 16 h (lane 4), 20 h (lane 5), or 24 h (lane 6), or infected MEF cultured in the presence of PAA for 24 h (lane
7). The blot was sequentially probed with (B) a full-length M73.5 cDNA probe; (C) a M72-specific DNA probe (residues 102,876–103,535); (D) a M73-
specific DNA probe (residues 104,096–104,248); (E) a m74-specific DNA probe (residues 104,636–105,053); (F) a M73.5 exon-2-specific DNA probe
(residues 105,881–106,055); (G) a 907-bp M55 (gB)-specific probe amplified using the gB-specific primers GATCcCTGAACAACGATCG and
CGGTGATATCTCGACGAC (Xu et al., 1996); and (H) a mouse h-actin-specific probe. Molecular weight estimates of the detected transcripts were
determined relative to 0.28–6.58-kb RNA markers (Promega).
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that initiates at position 103,985 with splice donor and
acceptor sites at 104,160 and 105,879, respectively. The
larger 650-bp fragment corresponds to a spliced transcript
with exon 1 spanning nucleotides 103,985–104,548 and
exon 2 spanning nucleotides 105,879 to 106,093. Inspection
of the sequence of this 5V-RACE PCR product indicates that
the M73 (gN) ORF is present in its entirety within exon 1 of
this transcript, suggesting that the MCMV M73 gene
encoding gN is also spliced. Thus, like the M73.5 transcript,
the M73 transcript also initiates at position 103,985, but has
a different splice donor site at 104,548. Finally, a plasmidclone corresponding to the faint band of approximately 200
bp was sequenced and found to represent a spliced mRNA
with exon 1 spanning nucleotides 94,984–95,063, and exon
2 spanning nucleotides 105,879–106,093. Thus, this tran-
script likely initiates at nucleotide 94,984 near the MCMV
origin of lytic replication, and has an intron of over 10.8 kb.
As no other genes have been designated for the region
between m59 and M69 (Rawlinson et al., 1996), this
putative MCMV transcript has been designated m60. The
putative m60 protein comprises eight amino acids encoded
within exon 1 and 64 amino acids from exon 2, which are
shared with M73.5.
Table 1
MCMV-specific primers used in this study
Primer designation Primer sequence (5V–3V)a Genomic coordinatesb




M73A-Not1-Rev cctcgcggccgCGGCTCAATATCCTTTAGCCGTG 104,523–104,501 (C)
M73ArevE1Tag acgtggaattccATATCCTTTAGCCGTGTC 104,516–104,499 (C)
M73B GAGGATCCGCTCGCCATGGC 104,251–104,232 (C)
TS9-EcoRV-For ccacgatatcatgAGTCTCTGCGGAGCGCGATG 105,881–105,900
TS9-Not1-Rev ccacgcggccgcTCTTTATTGCGTCGAGCACCC 106,075–106,055 (C)
M73CrevE1Tag acgtggaattccTTGCGTCGAGCACCCCCCGCA 106,069–106,049 (C)
M73D-Ori-FBH1 tatggatCCTATGACCGTATATGGGGTGTC 95,036–95,058
Ori-TS9-For1 CAGAGCCTAAGTGTCCATCG 94,984–95,003
TS91 CATCTTGGAATCCGACGATGGCTC 105,983–105,960 (C)
TS94 CTCGGTACAACACCAACATC 105,962–105,943 (C)
a MCMV-derived sequences are shown in upper case. Underlined sequences denote restriction sites introduced into the oligonucleotide.
b The genomic coordinates are based on the published nucleotide positions given for the Smith strain of MCMV (Rawlinson et al., 1996). C = complementary
strand.
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apparently share exon sequences in the m74-M75 intergenic
region, 3V-RACE PCR was performed using the M73A-
EcoRV-For or Ori-TS9-For1 primers (see Table 1) together
with an oligo-dT17-adaptor primer. With the M73A-EcoRV-
For/oligo-dT17-adaptor primer combination, PCR products
migrating at approximately 300 and 700 bp were obtained
(Fig. 4A, lane 14). These PCR products were again cloned
into the pGEM-T vector and sequenced. The 300-bp
fragment is likely derived from the spliced M73.5 transcript.
It spans the exon 1 sequence between the primer-binding
site at 104,096 and the splice donor site at 104,160,
continues through the entire exon 2 sequence (nucleotides
105,879–106,093), and ends with a poly(A) tail. The larger
700-bp fragment corresponds to the M73 transcript. It
begins with exon 1 sequences between the primer-binding
site at 104,096 and the splice donor site at 104,548,
continues with the same exon 2 sequence as the M73.5
transcript (105,879 to 106,093), and ends with a poly(A)
tail. 3V-RACE PCR performed with the Ori-TS9-For1 primer
and oligo-dT17-adaptor generated PCR products of approx-
imately 300, 700, and 800 bp (Fig. 4B, lane 5). Sequencing
of the 300-bp fragment yielded an exon 1 sequence from
94,984 to 95,064, and exon 2 sequences (105,879 to
106,093) corresponding to the m60 transcript described
above. The 700- and 800-bp products corresponded to
nonspecifically amplified mouse sequences. Thus, all three
transcripts (m60, M73, and M73.5) appeared to share the
same exon 2 sequences and terminate at nucleotide position
106,093.
The 5V- and 3V-RACE PCR analyses were confirmed by
RT-PCR analysis. The initial reverse transcription (RT)
utilized the TS9-Not1-Rev primer (106,075–106,055).
When RT-PCR was carried out with the M73A-EcoRV-
For and TS9-Not1-Rev primers, three PCR products were
obtained, with the 300- and 700-bp products corresponding
to the M73.5 and M73 transcripts, respectively (Fig. 4A,lane 10). The 600-bp product corresponded to a nonspecifi-
cally amplified mouse sequence. RT-PCR with Ori-TS9-
For1 and TS9-Not1-Rev primers yielded a single product of
approximately 300 bp corresponding to the m60 transcript
(Fig. 4B, lane 2). Therefore, our analysis thus far suggests
that the 0.3–0.4, 0.45–0.6, and 0.75–0.9 kb spliced tran-
scripts detected by Northern analysis likely correspond to
mRNAs encoding the m60, M73.5, and M73 proteins,
respectively.
Finally, the 1.1–1.2-kb transcript detected by Northern
analysis is likely to be spliced, and may represent
mRNAs with alternate initiation sites further upstream.
Thus, additional 5V-RACE PCR analyses were performed
with primers upstream of the primary initiation site at
103,985. The TS9-Not1-For primer (see Table 1) was
used for priming the reverse transcription. Then, the TS91
and M72-Seq5 primers (Table 1) were used for primary
and nested PCR, respectively, yielding a nested 5V-RACE
PCR product of 200 bp (Fig. 3B, lane 2). Sequencing of
this product indicated that it initiated from 103,700. To
verify that mRNAs initiating at 103,700 also extend
through the M73/M73.5 exon 2 sequences, RT-PCR and
3V-RACE PCR were performed using the M72-Seq8
primer (103,766–103,784) in conjunction with the TS9-
Not1-Rev (Table 1) or oligo(dT)17-adaptor primers,
respectively. These reactions yielded PCR products
corresponding to longer versions of M73 and M73.5
(Fig. 4A, lanes 2 and 6), suggesting that both M73 and
M73.5 transcripts may initiate from an alternate tran-
scription initiation site (103,700) 285 bp upstream of the
primary initiation site at 103,985. Both transcription
initiation sites at 103,700 and 103,985 have potential
TATA boxes (Bucher, 1990) (103,669-AATAAC-103,674)
and (103,954-TATTTA-103,959) approximately 30 nucleo-
tides upstream. In addition, dCAT cap signals are located
at the transcription initiation sites (103,700–103,701) and
(103,985–103,987).
Fig. 3. Characterization of the M73 family of spliced transcripts by 5V
RACE PCR analysis. Mapping of 5V-ends of transcripts by 5V-RACE PCR
was performed on total RNA isolated from MCMV-infected MEFs at 24 h
p.i. Primary 5V-RACE PCR was performed with gene-specific primer TS91
(see Table 1) and nested PCR was performed using the gene specific
primers TS94 (A) and M72-Seq5 (B) on first-strand cDNA generated plus
(lane 2) or minus (lane 3) reverse transcriptase during the initial reverse
transcription step.
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RT-PCR experiments indicate that transcription from the
M72-M75 region is complex and supports the existenceFig. 4. Characterization of the M73 family of spliced transcripts by RT-PCR and 3V
strand cDNA prepared from poly(A)+ RNA isolated from MEF infected for 24 h
combinations M72-Seq8 (A, lanes 2–5), M73A-EcoRV-For (A, lanes 10–13), or O
templates prepared with (A, lanes 2 and 10; B, lane 2) or without (A, lanes 3 and
Water alone controls are shown (A, lanes 5 and 13; B, lane 4). Control PCR on M
EcoRV-For (A, lane 12) and TS9-Not1-Rev. 3V-RACE PCR mapping was perform
6–8), M73A-EcoRV-For (A, lanes 14–16), or Ori-TS9-For1 (B, lanes 5–7) and (d
14; B, lane 5) or without (A, lanes 7 and 15; B, lane 6) reverse transcriptase during
and 16; B, lane 7).of at least 5 novel 3V co-terminal spliced MCMV tran-
scripts that share the same splice acceptor sites, but differ
in their 5V-exons, splice donor sites, and transcription
initiation sites. The nucleotide sequence coordinates of
each of these characterized transcripts are summarized in
Fig. 2A.
Characterization of the proteins encoded by the MCMV
spliced transcripts
The detection of proteins encoded by these spliced
MCMV transcripts was facilitated initially by the con-
struction of expression plasmids in which c-myc tags were
attached to the C-termini of each of the three putative
ORFs (m60, M73/gN, and M73.5). Each plasmid construct
was transfected into COS-7 cells and protein expression
monitored by Western blotting using the anti-c-myc
monoclonal antibody 9E10. Fig. 5A shows that the M73
(lane 3), M73.5 (lane 2), and m60 (lane 4) gene products
were expressed as approximately 15, 14, and 8 kDa
proteins, respectively. Furthermore, a 16-kDa protein and a
series of fainter 22–26-kDa bands were also detected in
cells transfected with the gpM73.5 expressing plasmid
(lane 2). The fact that hyperimmune serum to MCMV
detected the 14- and 15-kDa proteins (Fig. 5B, lanes 2 and
3), indicated that the M73.5 and M73 gene products are
expressed as immunogenic proteins during virus infection
in vivo.
The subcellular locations of these proteins were initially
determined by confocal microscopy in COS-7 cells trans--RACE PCR analysis. RT-PCR and 3V-RACE PCR were performed on first-
. RT-PCR analysis was performed on first-strand cDNA using the primer
ri-TS9-For1 (B, lanes 2–4) and TS9-Not1-Rev. RT-PCR was performed on
11; B, lane 3) reverse transcriptase during the first-strand cDNA synthesis.
CMV genomic DNAwas performed with M72-Seq8 (A, lane 4), or M73A-
ed on first-strand cDNA using the primer combinations M72-Seq8 (A, lanes
T)17-adaptor primer. PCR was performed on templates with (A, lanes 6 and
the first-strand cDNA synthesis. Water alone controls are shown (A, lanes 8
Fig. 5. Western blot analysis of the proteins expressed by the 3V-coterminal
transcripts and reactivity of the anti-M73.5 MAb CF24 against viral
proteins. The M73, M73.5, and m60 ORFs were amplified by PCR and
cloned into the vector pcDNAtag, and for M73.5 into pcDNA-3 also. Each
construct was transfected into COS-7 cells and then lysates prepared at 48 h
post-transfection. In panels A, B, and C, lysates from COS-7 cells
transfected with pcDNAtag (lane 1), pcDNAtag-M73.5 (lane 2), pcDNA-
tag-M73 (lane 3), pcDNAtag-m60 (lane 4), or pcDNA-M73.5 (lane 5, panel
C only) were separated on 12% Bis–Tris gels before Western blot analysis
with specific antibodies. Replicate blots were incubated with either anti-c-
myc MAb 9E10 (A), or murine anti-MCMV hyperimmune serum (B), or
MAb CF24 (C) as primary antibodies. Reactivity of MAb CF24 against
virally encoded proteins was assessed in MCMV-infected MEFs (D).
Mouse embryo fibroblasts were infected with MCMV for 1 day (lane 2), or
5 days (lane 3), or left uninfected (lane 1). Cell lysates were separated on
12% Bis–Tris gels before Western transfer and detection with MAb CF24.
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paragraph) because of the high transfection efficiency in
these cells (Fig 6A). All three c-myc-tagged fusion proteins
(m60, M73, and M73.5) were detected within the cytoplasm
of permeabilized, transfected cells with the anti-c-myc MAb
9E10 (Figs. 6b–d). Interestingly, the M73.5 and m60
proteins (Figs. 6f–g), but not the M73 protein (Fig. 6h),
could be detected on the cell surface of nonpermeabilized,
transfected COS-7 cells. As the MAb 9E10 recognizes the c-
myc tag at the C-termini of the m60 and M73.5 fusion
proteins, their detection on the cell surface of nonpermea-
bilized cells supports the concept that they are type II
glycoproteins.
To confirm our findings in cells that are normally
permissive for MCMV replication, we carried out similarexperiments in Balb/3T3 fibroblasts (Fig. 6B). In addition,
cells were infected with MCMV 6 h before they were
processed for immunofluorescence. Thus, detection of the
M112-113 gene products, a family of early proteins (also
known as E1 proteins) localized exclusively to the nuclei of
infected cells (Bqhler et al., 1990; Ciocco-Schmitt et al.,
2002), could be used as an internal control for the
permeability of transfected cells. Meanwhile, the m60,
M73, and M73.5 proteins detected in these cells could only
be derived from the transfected cDNA because late genes
are not expected to be expressed at this stage of the MCMV
infection. As shown in Fig. 6B, the c-myc-tagged m60 and
M73.5 fusion proteins were detected by MAb 9E10 on the
cell surface (panels b and c) of nonpermeabilized cells as
well as the cytoplasm of permeabilized cells (panels f and
g). While the characteristic nuclear fluorescence of E1
proteins in permeabilized cells (panels e to i, k) was readily
detectable by rabbit antibodies raised against these proteins,
the inability of the antisera to detect these nuclear proteins in
nonpermeabilized cells (panels a to d, j) demonstrated
convincingly that the c-myc tag at the C-terminus of the
fusion proteins detected by 9E10 must indeed be present on
the surface of these cells, thereby confirming our previous
conclusion that both m60 and M73.5 encode type II
glycoproteins. The detection of the c-myc-tagged M73
protein on the cell surface of transfected Balb/3T3 cells by
9E10 (Fig. 6B, panel d) would seem to imply that M73
encodes a type II glycoprotein and the expression/topology
of the protein may differ between Balb/3T3 and COS-7
cells. However, we felt that this conclusion is premature
because of the small number of cells positive for 9E10 as a
result of the low efficiency of transfection in Balb/3T3 cells
and the lack of additional evidence on the subcellular
location of wild type M73 expressed during MCMV
infection.
To better characterize these related gene products, a MAb
designated CF24 (IgG2a isotype) was specifically raised
against gpM73.5 by immunizing C57BL/6J mice with the
M73.5-c-Myc fusion protein. The specificity of this MAb
was assessed by Western blot analysis of lysates of COS-7
cells transfected with plasmids expressing the c-myc-tagged
M73.5, M73, or m60 proteins, or untagged gpM73.5 (Fig.
5C). Monoclonal antibody CF24 showed strong reactivity
against both the c-myc-tagged and unmodified M73.5
proteins (lanes 2 and 5, respectively) with very weak
cross-reactivity against the M73 protein (lane 3), and no
reactivity against the m60 protein (lane 4). The lack of
reactivity of MAb CF24 with m60 and its very weak cross-
reactivity with M73 suggest that CF24 may recognize an
epitope spanning the exon 1/2 boundary of M73.5. It is
interesting to note that the MAb CF24 detected a broad 22–
26-kDa band rather than a series of distinct bands in that
size range when unmodified M73.5 was transiently
expressed (compare lanes 2 and 5), suggesting that the
addition of the C-terminal c-myc tag not only increases the
sizes of the M73.5 gene products, but may also affect the
Fig. 6. Surface expression of M73.5- and m60-encoded proteins. (A) COS-7 cells were transfected with pcDNAtag (panels a, e), pcDNAtag-M73.5 (panels b,
f), pcDNAtag-m60 (panels c, g), or pcDNAtag-M73 (panels d, h) plasmids. Following transfection, cells were permeabilized (a–d) or left unpermeabilized (e–
h), stained with the anti-c-myc MAb (9E10) and then AlexaFluor 488-conjugated goat–anti-mouse Ig secondary antibody (green) before being finally incubated
with Hoeschst 33342 to visualize nuclei (blue). Transfected cells were then visualized by confocal microscopy. The scale bars are 20 Am. (B) Balb/3T3
fibroblasts were transfected with pcDNAtag (panels a, e), pcDNAtag-M73.5 (panels c, g), pcDNAtag-m60 (panels b, f, and i), or pcDNAtag-M73 (panels d, h)
plasmids. Six hours before these cells were processed for immunofluorescence, they were superinfected with MCMV (Smith strain). In contrast, untransfected
Balb/3T3 fibroblasts (panels j, k) were infected with MCMV (Smith strain) and processed for immunofluorescence at 24 h post-infection. At 48 h post-
transfection, cells were fixed in 3.75% formaldehyde, and either permeabilized (panels e to i, k), or left unpermeabilized (panels a to d, j) as described in
Materials and methods. The subcellular locations of the expressed proteins were visualized under a fluorescence microscope after cells were stained with the
monoclonal antibodies 9E10 (panels a to h) or 6A1.21A (panels i to k), followed by incubation with rhodamine-conjugated goat anti-mouse antibodies (red).
The permeability of the cells in all panels was monitored by staining with rabbit anti-E1 polyclonal antibodies followed by incubation with FITC-conjugated
goat anti-rabbit antibody (green). Color images (red and green) were captured by a digital camera, and then superimposed and analyzed with the tools built into
the public domain program Image J (available at http://rsb.info.nih.gov/ij). Final images were prepared for publication using Adobe Photoshop CS and Adobe
Illustrator CS.
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reacts with M73.5 proteins in MCMV-infected cells,
detecting a 14-kDa band and a broad 22–28-kDa band
(Fig. 5D, lanes 2 and 3).The M73.5 gene encodes the gp24 virion glycoprotein
The characteristics of the M73.5-encoded gene products
are reminiscent of a previously described MCMV virion
Fig. 7. M73.5 encodes the gp24 MCMV virion glycoprotein. 3T3-L1
fibroblasts infected with MCMV (lanes 1, 3, and 4) or COS-1 cells
transfected with the plasmid pSV-gp24 (lanes 2 and 5) were radiolabeled
with [35S]methionine, solubilized in immunoprecipitation buffer and
precipitated with either MAb 8B6.21A (lanes 1 and 2) or MAb 6A1.21A
(lanes 3–5) as described in Materials and methods. The precipitated proteins
were either digested with Endoglycosidase F (lanes 4 and 5) or left
untreated (lanes 1–3) before separation on a 12% SDS-polyacrylamide gel
and visualization by autoradiography. The numbers on the left represent the
sizes of molecular weight markers. The abbreviations above each lane
indicate whether the proteins were derived from transfected (Tf) or infected
(Inf) cells.
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(Loh, 1989). For example, gp24 was found in virus-infected
cells as an 18.4-kDa precursor that matured into a 22–26-
kDa glycoprotein which was incorporated into MCMV
virions. The gp24 protein was also found on the surface of
virus-infected cells and possessed at least one N-linked
glycosylation site (Loh, 1989; Loh et al., 1991). To
investigate whether M73.5 encodes the gp24 glycoprotein,
the amino acid sequence of the latter was determined.
The gp24 glycoprotein and its 18.4-kDa precursor were
immunoprecipitated from MCMV-infected fibroblasts with
MAb 6A1.21A and purified on a 12% SDS-polyacrylamide
gel as described in Materials and methods. As gp24 co-
migrated with the light chain of the precipitating antibody,
only the 18.4-kDa band was excised from the gel and
subjected to tryptic digestion bin gelQ. Sequence information
of the resulting peptides was determined by microcapillary
reverse-phase chromatography coupled to the nano-electro-
spray ionization source of a quadrupole ion trap mass
spectrometer (Chittum et al., 1998; LeRoy et al., 1998). Two
of the peptide sequences, bTGAGSLCGARQ and
bAIVGFQDDIVLRQ, corresponded exactly to amino acids
18–27 and 49–60, respectively, of the predicted amino acid
sequence for the M73.5 gene product (Fig. 1). In particular,
the first peptide sequence spans the splice site between exon
1 and exon 2, thereby providing direct confirmation of the
presence of the splice site. Thus, our protein sequencing
data supports the hypothesis that the MCMV virion
glycoprotein gp24 is encoded by M73.5.
To provide additional confirmation of the identity of
gp24 and gpM73.5, the expression of the gp24/gpM73.5
glycoprotein was monitored during MCMV infection of
3T3-L1 fibroblasts and in COS-1 cells transfected with the
expression plasmid pSV-gp24 (described in Materials and
methods). As the NruI–BglII genomic fragment, which only
contains the M73 and M73.5 ORFs, was placed behind the
SV40 early promoter in pSV-gp24, the m60 protein should
not be expressed after transfection. As shown in Fig. 7, both
the 18.4-kDa precursor and 22–26-kDa gp24 were specif-
ically immunoprecipitated from infected or transfected cells
by MAbs 8B6.21A and 6A1.21A (lanes 1 to 3). Further-
more, digestion with Endoglycosidase F, which removed N-
linked carbohydrate moieties, reduced the sizes of precursor
and mature forms of gp24 in both infected and transfected
cells to their unglycosylated size of 14.6 kDa (lanes 4 and
5), suggesting that the unique N-linked glycosylation site in
exon 2 of M73.5 is probably utilized. The approximately 32
kDa bands (lanes 4 and 5) likely represented uncharacter-
ized deglycosylated products that co-precipitated with the
gp24/gpM73.5 proteins. In addition, deletion of exon 2
sequences from pSV-gp24 abolished the expression of gp24
(data not shown). Thus, our data confirmed the identity of
gp24 and the gpM73.5. It is interesting to note that a
significantly higher percentage of the M73.5 protein
migrated at the size of its unglycosylated form in transfected
COS-1 cells than in infected cells (compare lanes 1 and 2).Perhaps the addition of N-linked carbohydrates to gp24/
gpM73.5 is inefficient in COS-1 cells in the absence of virus
infection. Finally, minor differences in size estimates
between Figs. 5 and 7 may be accounted for by the use of
different molecular weight markers and/or types of poly-
acrylamide gels.
As M73.5 and m60 share exon 2 sequences, we
investigated if the gpM73.5-specific MAb 6A1.21A was
able to recognize the m60 fusion protein expressed in
permeabilized, MCMV-infected, pcDNAtag-m60-trans-
fected cells (Fig. 6B, panel i). The reactivity of 6A1.21A
with these cells indicates that the epitope recognized by
this MAb is located at the C-terminal half of the m60 and
M73.5 proteins. Furthermore, the reactivity of 6A1.21A on
unpermeablized, infected cells (Fig. 6B, panel j) suggested
that wild-type gpM73.5/gpm60 synthesized during MCMV
infection likely reflects their type II glycoprotein config-
uration, and the presence of the c-myc tag in the fusion
proteins did not affect their topology. Uninfected Balb/3T3
cells showed no reactivity with 6A1.21A (data not
shown).
Genetic polymorphisms in M73 and M73.5
Previous sequence analyses of the HCMV UL73 ORF
have revealed that this protein appears to be highly variable
among clinical isolates (Dal Monte et al., 2001; Pignatelli et
al., 2001; 2003), suggesting that either the UL73-encoded
gN molecule is subjected to substantial immunological
pressure for the selection of variant sequences or that these
gN variants may have distinct functions. To determine
whether the MCMV M73 (gN) homolog and the M73.5
A.A. Scalzo et al. / Virology 329 (2004) 234–250 243protein are equally highly polymorphic, we performed
sequence analyses of these genes from a panel of MCMV
field isolates (Booth et al., 1993). The M73 ORF and M73.5
exon 2 sequences were amplified by PCR and pooled PCR
products from replicate PCR reactions were subjected to
sequence analysis. Fig. 8A shows that in a subset of
approximately one-third of the field isolates tested, the M73
gene exhibited a modest degree of polymorphism from the
laboratory strain K181 in the central portion of the protein.
However, the extent of variation was less than that for
HCMV UL73 and does not support the notion of extensive
M73 genotypes as observed for HCMV UL73. Unlike M73,
the exon 2 region amino acid sequence of the M73.5 protein
is very highly conserved (Fig. 8B). A subset of 5 of only the
18 field isolates tested exhibited an additional glycine
residue at position 80 of the protein sequence.
The M73.5/m60 ORF encoded within exon 2 is conserved
among betaherpesviruses
The existence of spliced M73.5 and m60 genes had not
been predicted previously during analysis of the complete
MCMV sequence (Rawlinson et al., 1996). Hence, it is of
considerable interest to determine whether protein coding
sequences similar to M73.5 exist in other herpesviruses. To
this end, the protein sequence of M73.5 was used to searchFig. 8. Comparison of the deduced amino acid sequences of M73 (panel A) and M
isolates are compared to the K181 strain sequence shown at the top for both pr
included where amino acid insertions are present in some strains.nucleotide databases using the TBLASTN algorithm
(Altschul et al., 1990). Significant homologies exist
between the protein sequence of M73.5/m60 encoded
within exon 2 and translated protein sequences present in
all betaherpesviruses that have been sequenced to date
(Fig. 9). The level of sequence identity varied from 30% to
46%. Furthermore, these deduced protein sequences are all
conserved in their location between betaherpesvirus homo-
logs of m74 (gO) and M75 (gH). However, similar
homologous sequences were not identified in any alpha-
or gammaherpesviruses. Thus, our data suggest the
existence of a hitherto unidentified betaherpesvirus-specific
glycoprotein.
A number of other striking similarities are present
between the MCMV M73.5 gene exon 2 coding sequence
and other homologous betaherpesvirus sequences. First, all
of the betaherpesvirus M73.5 dexon 2T sequence homologs
are bounded at their 5V ends by potential splice acceptor sites
(Senapathy et al., 1990) (Table 2). Second, the sequences
are flanked at the 3V ends by consensus polyadenylation
signals that overlap, or are near, the putative stop codons
(Table 2). Third, the predicted amino acid sequences exhibit
remarkably similar hydrophilicity profiles, characterized by
conserved hydrophobic stretches, consistent with membrane
spanning domains, followed by a relatively hydrophilic
C-terminal tail (data not shown). In addition, a highly73.5 exon 2 (panel B) sequences from MCMV isolated from wild mice. All
oteins. Dots indicate sequence identity to the K181 sequence. Dashes are
Fig. 9. Alignment of translated exon 2 sequences of putative betaherpesvirus M73.5 homologs. Translated sequences showing homology to the MCMV M73.5
exon 2 sequences were identified using the TBLASTN algorithm. Shown here are the alignments of the amino acid sequences. Shaded in black are conserved
amino acids. The consensus sequence is based on least three of the betaherpesviruses sharing the same translated amino acid residue. Shown in lower case are
conserved C-terminal N-linked glycosylation sites (N-X-T/S).
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MCMV M73.5 is located within the putative membrane-
spanning domain (Fig. 9). Finally, each sequence contains at
least one consensus N-linked glycosylation site (N-X-S/T) in
the hydrophilic C-terminal region of the putative gene
product (Fig. 9). Overall, these similarities strongly suggest
that all betaherpesviruses encode spliced gene products
homologous to M73.5, which may play an important role in
the betaherpesvirus life cycle.Discussion
The replication of herpesviruses in host cells is depend-
ent on suites of proteins that are conserved among all
herpesviruses. However, there are proteins that are only
expressed in certain herpesvirus subfamilies and these play
critical roles in the replication strategies of viruses of that
particular subfamily. In this study, we have analyzed a
family of spliced transcripts expressed in murine cytome-
galovirus. Two of these spliced mRNAs (M73) encode gN,
which is conserved in all herpesviruses (Davison, 2002),Table 2
Splice acceptor sequences, stop and polyadenylation signals found adjoining the
Virus Splice acceptor Stop codon
Sequencea Location Sequence L
MCMV TCTCTTTGTGTTTTAATAGG 105,860–105,879 TAA 1
THV CTCTTCATGTCTCTCGCAGG 120,538–120,557 TAA 1
RCMV TCGCGGTCTCCCTTCCGAGG 93,953–93,972 TGA
GPCMV TTCTTTCTCGTTTCGTTAGG 2730–2711b TAG
RhCMV TGCTTTTTTCTTACTGCAGG 98,726–98,745 TGA
CCMV CCGTGTCTTGCCATTGCAGG 108,521–108,540 TAA 1
HCMV TTTTCTCCCCATGACAGAGG 107,514–107,533 TAA 1
HHV6 GTATTTGCTTTTTTTATAGG 77,823–77,842 TAA
HHV7 TATTCATTTTTTTAACCAGG 74,845–74,864 TAA
a Consensus splice acceptor sequence is NTNYTYYYYYYYYYYNCAGG (Sen
b Complementary strand.whereas the other spliced transcripts (M73.5 and m60)
encode proteins that appear to share strong sequence
homologies to a putative glycoprotein species present in
all betaherpesviruses that have been sequenced to date.
Furthermore, we have shown the M73.5 gene encodes the
structural viral glycoprotein gp24 recognized by the
neutralizing antibody 6A1.21A (Loh, 1989).
Northern blot analysis utilizing probes spanning the
region M72–M75 indicates that this region is transcrip-
tionally complex. All probes detected a 3.8-kb transcript,
and probes from M72 to m74 detected a 2.6-kb transcript.
These transcripts possibly correspond to the 5.0- and 3.1-
kb transcripts reported previously (Rapp et al., 1994)
using probes specific for gH (M75) and dUTPase (M72).
Rapp et al. (1994) concluded that the 5.0-kb transcript
corresponds to the gH transcript that terminates at a
polyA signal downstream of dUTPase (M72). The 2.6-kb
transcript may represent a polycistronic mRNA encom-
passing the M72 and m74 ORFs, which are encoded on
the complementary strand (Rawlinson et al., 1996). The
precise origin of the 1.7-kb late transcript was not








06,070–106,072 106,068–106,073 U68299 Rawlinson et al.,
1996
20,744–120,746 120,792–120,797 AF281817 Bahr and Darai, 2001
94,202–94,204 94,211–94,216 AF046125 Vink et al., 2000
2719–2717b 2459–2454b U49361 Brady and Schleiss,
1996
98,973–98,975 98,975–98,980 AY186194 Hansen et al., 2003
08,739–108,741 108,741–108,746 AF480884 Davison et al., 2003
07,727–107,729 107,727–107,734 X17403 Chee et al., 1990
78,013–78,015 78,021–78,026 X83413 Gompels et al., 1995
75,036–75,038 75,183–75,188 AF037218 Megaw et al., 1998
apathy et al., 1990).
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M75.
The Northern blot analyses also revealed that probes
specific for M73 and the intergenic region between m74 and
M75 detected a 1.1-kb leaky late transcript in addition to the
abundant 0.45–0.6- and 0.75–0.9-kb transcripts. The 5V-
RACE PCR and 3V-RACE PCR analyses performed indicate
that the 1.1-kb transcript is a longer version of the M73
transcript that initiates from an upstream site. The RACE-
PCR data indicate that a longer version of the M73.5
transcript also initiates from the upstream initiation site at
103,700. Both the upstream (103,700) and downstream
(103,985) transcription sites have potential TATA box and
cap signal elements. The expression of the MCMV M73
(gN) gene as a spliced transcript raises the question of
whether HCMV UL73 (gN) is also expressed as a spliced
transcript. Studies conducted so far to characterize the
expression of the HCMV UL73 protein have not addressed
the nature of the UL73 transcript (Dal Monte et al., 2001;
Mach et al., 2000). A potential splice donor site (106,189-
GGG/GTAAGG-106,197) lies downstream of the stop
codon of UL73 and may correspond to the splice donor
site observed in MCMV.
The conservation of sequence homologs of the M73.5/
m60 exon-2-encoded protein sequence in all sequenced
betaherpesviruses suggests that the M73.5/m60 protein(s)
may serve an important betaherpesvirus-specific function.
The characteristics of the M73.5 and m60 proteins indicate
that they are type II, rather than type I, integral membrane
glycoproteins. This finding is supported by the observation
that the M73.5 and m60 proteins were detected on the
surface of nonpermeabilized, transfected Balb/3T3 and
COS-7 cells, implying that the C-terminal c-myc tag must
be expressed on the exterior surface of the cell. Rat CMV
has been shown to encode a spliced C-type lectin-like-
protein with the characteristics of a type II membrane
protein (Voigt et al., 2001). However, to our knowledge,
only one other CMV type II membrane protein (M50/p35)
has been reported (Muranyi et al., 2002). Other herpesvi-
ruses have been shown to encode type II membrane
proteins, which include herpes simplex virus type 2 UL34,
UL45 and UL56, Varicella-zoster virus ORF65, and
Pseudorabies virus Us9 (Brideau et al., 2000; Cockrell
and Muggeridge, 1998; Cohen et al., 2001; Koshizuka et al.,
2002; Shiba et al., 2000).
Our finding that M73.5 encodes the gp24 structural
glycoprotein recognized by the neutralizing MAb 6A1.21A
(Loh, 1989) indicates that this novel type II glycoprotein is
likely to play an important role during virus attachment or
entry into target cells. One very interesting feature of the
deduced protein sequences of the M73.5/gp24 homologs is
that they all share a conserved, positively charged arginine
residue in the putative transmembrane domain. Charged
residues in the transmembrane domains of foamy virus
envelope protein (Pietschmann et al., 2000) and hepatitis C
virus E1 and E2 proteins (Cocquerel et al., 2000) have beenshown to play roles in membrane fusion and assembly of the
virus envelope, respectively. Hence, the conserved arginine
residue of the M73.5/m60 betaherpesvirus homologs may
have a functional role in betaherpesviral replication or
morphogenesis.
Analysis of the level of sequence variation of the
MCMV M73 and M73.5 exon 2 protein sequences
revealed that M73 exhibits a modest level of sequence
variation within MCMV strains derived from wild mice,
whereas the M73.5 exon 2 protein sequences are highly
conserved. The M73 sequences possibly belong to two
sequence groups, one being very similar to the prototype
laboratory strains Smith and K181, and the other having
four to seven amino acids that have diverged from the
Smith sequence. This is a different situation to the
hypervariability found in clinical isolates for HCMV
UL73, where the UL73 sequences fall into seven distinct
groups (gN1, gN2, gN3a, gN3b, gN4a, gN4b, and gN4c),
which have levels of divergence from the AD169
sequence ranging from 16.4% to 24.1% (Pignatelli et
al., 2001, 2003). The lower level of variability in MCMV
M73 may mean that the MCMV gN glycoprotein is not
subjected to the same selective pressures as HCMV UL73.
Similarly, the strong sequence conservation of the
gpM73.5 protein among MCMV strains implies that either
variation in this protein is constrained due to structure or
function, or that it is not subjected to extensive
immunological pressure from neutralizing antibodies.
However, as the MCMV M73.5 cDNA was originally
identified by screening of a cDNA expression library with
anti-MCMV hyperimmune serum, this indicates the M73.5
protein is immunogenic during viral infection. Further-
more, as the 6A1.21A MAb is a neutralizing antibody,
this suggests that gpM73.5/gp24 should be subjected to
immunological pressure.
As shown in this study, MCMV possesses a family of
spliced 3V-co-terminal transcripts that share a common exon 2
sequence in the intergenic region betweenm74 andM75. The
translated exon 2 coding sequence of the M73.5/m60 tran-
scripts is highly conserved among all of the betaherpesviruses
sequenced to date. Further analyses of the role of the M73.5/
m60 proteins in MCMV replication by disruption muta-
genesis, together with the site-directed mutagenesis of the
conserved residues and motifs such as the charged residue in
the transmembrane domain of this protein, or the unique N-
linked glycosylation site, will help us understand the role of
this conserved protein(s) during betaherpesviral replication.Materials and methods
Cells
Primary mouse embryo fibroblasts (MEFs) were pre-
pared by trypsin dispersion of 15–17-day-old embryos from
outbred ARC(S) mice (Animal Resources Centre, Murdoch,
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1977). MEFs were cultured in minimal essential medium
(MEM; Invitrogen Australia) supplemented with 10% fetal
calf serum (FCS; Invitrogen), 100 U/mL penicillin, and 40
Ag/mL gentamicin. COS-7, COS-1, mouse 3T3-L1, and
Balb/3T3 cells were cultured in Dulbecco’s MEM (DMEM,
Invitrogen) supplemented with 10% FCS, 100 U/mL
penicillin, and 40 Ag/mL gentamicin. For transfection of
COS-7 cells, OPTI-MEM 1 was used as the culture medium
(Invitrogen). Hybridomas were grown in RPMI-1640
(Invitrogen) supplemented with 10% FCS, 100 U/mL
penicillin, and 40 Ag/mL gentamicin.
Viruses and polyclonal antisera
Viruses used in this study were the K181, Smith, and
Vancouver laboratory strains of MCMV, together with a
panel of strains isolated from wild mice (Booth et al., 1993).
These were the G2, G3C, G4, G5, G6, K4, K7, K10, K17A,
K17B, K29, N1, W2, W3, W4, W5, W6, W7, W8, W9,
W9077, and WE6 strains. Tissue culture passaged stocks
were propagated by in vitro infection of MEFs at a
multiplicity of infection (moi) of 0.1 and harvested when
cultures showed 100% cytopathic effect. Virus stocks were
quantified by standard plaque assay on MEFs (Scalzo et al.,
1990). The preparation of a hyperimmune MCMV-specific
polyclonal antiserum to MCMV was as described previ-
ously (Dallas et al., 1994).
Screening of the MCMV cDNA library and subcloning
The preparation of a Egt11 cDNA library from poly(A)+
RNA from MCMV-infected cells at 24 h post-infection and
screening for MCMV DNA positive cDNA clones has been
described previously (Dallas et al., 1994). MCMV DNA
positive lambda clones were spotted onto lawns of
Escherichia coli Y1090 cells and screened with the
polyclonal hyperimmune MCMV-specific antiserum essen-
tially as described (Huynh et al., 1985). Positive clones were
amplified by PCR (Rasmussen et al., 1989) using Egt11
forward and reverse primers (Promega) and then cloned into
the pGEM11-Zf(+) plasmid vector.
DNA sequencing and analysis
DNA sequencing was performed on purified plasmid
DNA or on purified PCR products using the Applied
Biosystems Big-Dye version 3.0 or 3.1 sequencing kit
according to the manufacturer’s instructions. In all cases,
DNA sequences were determined on both strands. Over-
lapping sequence contigs were assembled using Vector NTI
v.5.3.0 (InforMax Inc., Bethesda, MD). Sequence data were
analyzed using the GCG suite of programs on WebANGIS
(http://www.angis.org.au/WebANGIS). Predicted protein
sequences were compared to nucleotide sequence databases
using the TBLASTN algorithm (Altschul et al., 1997).Preparation of RNA
Total RNA was isolated from MEFs infected with K181
MCMV strain at a moi of 5. Total RNAwas extracted using
RNAwiz reagent (Ambion, Austin, TX) at 4, 8, 16, 20, and
24 h post-infection. Total RNA was also extracted from
uninfected MEFs and from flasks of MEFs infected for 24 h
in the presence of 250 Ag/ml of phosphonoacetic acid, an
inhibitor of DNA synthesis. Total RNA was treated with
DNA-Free reagent (Ambion) to remove contaminating DNA.
Poly(A)+-selected RNAwas prepared from MCMV-infected
MEFs at 24 h p.i. using the Poly(A)Pure kit (Ambion).
Northern hybridizations
Total RNA samples (10 Ag) were glyoxylated, electro-
phoresed on 1.4% agarose gels in 10 mM NaH2PO4 buffer
(Sambrook et al., 1989), and then transferred to Hybond XL
membrane (Amersham). Membranes were prehybridized
for 1 h in Church–Gilbert buffer at 65 8C, before overnight
hybridization at 65 8C with 32P-labeled DNA probes in
fresh buffer. DNA probes were labeled with [32P]-dATP by
random priming according to the manufacturer’s instruc-
tions (DECAprime II, Ambion). After hybridization blots
were washed at 65 8C once for 15 min with 5  SSC
buffer/0.1% SDS, two times with 2  SSC buffer/0.1%
SDS, and once with 0.1  SSC buffer/0.1% SDS followed
by autoradiography.
RT-PCR and 5V and 3V RACE-PCR analyses
RT-PCR was performed on poly(A)+ RNA prepared from
MEFs at 24 h after MCMV infection. Following first-strand
cDNA synthesis with oligo-dT17-adaptor primer [5V-
GACTCGACGTCGACATCGA-(T)17-3V (Frohman et al.,
1988)], RT-PCR was performed with either the M73A-
EcoRV-For, M72-Seq8, or Ori-TS9-For1 forward primers
and the TS9-Not1-Rev primer (see Table 1). PCR products
were gel purified using the QIAquick gel extraction kit
(Qiagen, Valencia, CA) and then sequenced.
To map the 5V-ends of transcripts, 5V-RACE PCR was
performed according to the manufacturer’s instructions using
the 5V-RACE system, Version 2 (Invitrogen, Carlsbad, CA)
and total RNA derived from MCMV-infected MEFs at 24 h
p.i. The initial reverse transcription step was performed using
the TS9-Not1-Rev primer (see Table 1). The primary and
nested PCR reactions were performed using the TS91 and
TS94, or TS91 and M72-Seq5 gene-specific primers,
respectively. 5V-RACE PCR products were gel-purified,
cloned into pGEM-T (Promega) and then sequenced.
To map 3V-ends of transcripts, 3V-RACE PCR was
performed essentially as described (Frohman et al., 1988)
using the oligo-dT17-adaptor primer for first-strand cDNA
synthesis using poly(A)+ RNA. PCR was then performed
using either the M73A-EcoRV-For, Ori-TS9-For1, or M72-
Seq8 primers (see Table 1) and the oligo-dT17-adaptor
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or cloned into pGEM-T and then sequenced.
DNA manipulations
To generate C-terminally c-myc-tagged proteins, a
derivative of pcDNA-3 (Invitrogen) with a c-myc encoding
sequence inserted at the EcoRI site was constructed. This




annealed oligonucleotide pair was then ligated into the
EcoRI site of pcDNA-3. This vector, designated pcDNAtag,
retains a single EcoRI site to facilitate directional cloning, as
the site downstream of the stop codon after the c-myc
sequence was disrupted in the oligonucleotide pair. Plasmid
constructs expressing the M73, M73.5, and m60 ORFs in-
frame with a C-terminal c-myc tag were constructed by first
amplifying the respective ORFs by RT-PCR using the
M73forBamHI and M73ArevE1Tag, M73forBamH1 and
M73CrevE1Tag, and M37D-Ori-FBH1 and M73CrevE1Tag
primer combinations, respectively (see Table 1). Following
digestion of these PCR products with BamHI and EcoRI,
they were ligated into BamHI and EcoRI-digested pcDNA-
tag vector to give the appropriate constructs. The inserts
were sequenced to verify that no sequence errors were
introduced during PCR.
To construct the expression plasmid pSV-gp24, the 2.77-
kb NruI–BglII fragment was excised from the EcoRI-P
fragment of the MCMV (Vancouver strain) genome and
inserted between the BamHI and BglII cloning sites of the
plasmid vector pM1 (Sadowski et al., 1992). In particular,
the BglII site on pM1 was filled in with the Klenow
fragment of DNA polymerase I to facilitate ligation with the
NruI end of the insert. Thus, the shared ATG translation
start codon for the M73 and M73.5 ORFs was placed
approximately 70 bp downstream from the SV40 early
promoter, allowing the expression of both proteins. Exon 2
sequences can be removed from pSV-gp24 by digestion
with XbaI followed by self-ligation. The sequence of the
NruI–BglII fragment was verified by nucleotide sequencing
and was identical to the published sequence for the Smith
strain of MCMV (Rawlinson et al., 1996).
Transfections
For analysis of protein expression by Western blot, COS-
7 cells were cultured in 75-cm2 flasks. When just subcon-
fluent, the cells were transfected with 5 Ag of plasmid DNA
in OPTI-MEM medium containing Fugene transfection
reagent (Roche, Mannheim, Germany). Forty-eight hours
after transfection, the cells were lysed [10 mM Tris, pH 7.5;
1% NP-40; 150 mM NaCl, 1 Protease inhibitors (Roche)].
For immunofluorescence analyses, COS-7 cells (5  104)
were seeded onto glass coverslips and incubated overnight.The cells were then transfected with 0.5 Ag of plasmid DNA
in OPTI-MEM 1 medium and Fugene transfection reagent.
Transfection of the expression plasmid pSV-gp24 into COS-
1 cells by electroporation was carried out essentially as
previously described (Loh et al., 1994). Finally, Lipofect-
amine Plus reagent (Invitrogen) was used for the trans-
fection of Balb/3T3 fibroblasts with cDNA according to the
manufacturer’s instructions.
Anti-M73.5 monoclonal antibody production
To produce anti-M73.5 monoclonal antibody CF24
(IgG2a), C57BL/6J mice were injected two times by the
intraperitoneal (i.p.) route with 5  106 COS-7 cells
transfected with the M73.5 c-myc-tagged construct together
with 150 AL of MPL+ TDM adjuvant (Sigma). A final boost
of M73.5-c-myc COS-7-transfected cells plus MPL + TDM
adjuvant was injected by the i.p. route. Three days later,
splenocytes were removed and fused with X63 myeloma
cells as described (Harlow and Lane, 1988) and positive
clones identified by dot blot analysis.
Production of monoclonal antibodies against MCMV
proteins was previously described (Loh and Qualtiere,
1988). In particular, while both MAb 6A1.21A (IgM) and
the newly characterized MAb 8B6.21A (IgG3) recognized
gp24 in immunoprecipitation and immunofluorescence
assays, only 6A1.21A possessed neutralizing activity in
the presence of complement (Loh, 1989).
Western blot analyses
Lysates from untransfected or transfected COS-7 cells
were boiled in reducing or nonreducing sample buffers and
then electrophoresed on NuPAGE Novex 4–12% Bis–Tris
Gels (Invitrogen, Carlsbad, CA) at 200 V together with
SeeBlue Plus2 Prestained standards (Invitrogen). Following
electrophoresis, proteins were transferred to Trans-Blot
nitrocellulose membrane (Bio-Rad, Hercules, CA) before
incubation with the murine anti-c-myc MAb 9E10, or
murine polyclonal anti-MCMV hyperimmune serum, or
the anti-M73.5 MAb CF24, followed by alkaline phospha-
tase-conjugated goat anti-mouse Ig’s (Biosource Interna-
tional, Camarillo, CA) and detection with BCIP and NBT
substrates.
Immunofluorescence and confocal microscopy
Transfected or untransfected COS-7 cells on glass
coverslips were fixed with 4% paraformaldehyde and either
permeabilized by 0.1% Triton X100, or left unpermeabi-
lized. Cells were incubated with the murine anti-c-myc
monoclonal antibody (MAb) 9E10 or the murine polyclonal
anti-MCMV hyperimmune serum, followed by incubation
with AlexaFluor 488-conjugated Goat-anti-mouse Ig
(Molecular Probes, Eugene, OR) and incubation with the
nuclear stain Hoechst 33342. Cells were examined by
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1000/1024 UV laser scanning confocal microscope; Bio-
Rad, Hemel-Hempstead, U.K.). The program Confocal
Assistant was used to generate merged images.
To complement the confocal microscopy experiments,
Balb/3T3 cells grown on coverslips were processed for
immunofluorescence 48 h after DNA transfection as
previously described (Loh et al., 1999), with the exception
that the Triton X-100 treatment was omitted when
nonpermeabilized cells were required for monitoring sur-
face expression of glycoproteins. Immunofluorescence
images were captured digitally with a Zeiss Axioskop
microscope with an epifluorescence attachment using the
Northern Eclipse image analysis system and software
(Empix Imaging, Inc.). When simultaneous visualization
of two proteins under the fluorescence microscope was
required, cells were first stained with rabbit and mouse
antibodies specific for these proteins, and subsequently
incubated with goat anti-rabbit and anti-mouse antibodies
(Jackson Laboratories) conjugated to fluorescein isothio-
cyanate (FITC) or rhodamine, respectively. The two-color
images (green and red) were superimposed and analyzed
with the tools built into the public domain program Image
J (available at http://rsb.info.nih.gov/ij). Final images were
prepared for publication using Adobe Photoshop CS and
Adobe Illustrator CS.
Radiolabeling, immunoprecipitation, and Endoglycosidase
F digestion of viral glycoproteins
Mouse 3T3-L1 cells infected with the Smith strain of
MCMV at a moi of 5 were radiolabeled with [35S]methio-
nine (60 ACi/mL, New England Nuclear) between 21 and 44
h post-infection in RPMI media (Invitrogen) containing one-
tenth the normal amount of methionine. Similarly, COS-1
cells transfected with expression plasmids were radiolabeled
with [35S]methionine (60 ACi/mL) at 32 h post-transfection
for 14 h. Cells were lysed at the end of the labeling period
and the lysates immunoprecipitated with monoclonal anti-
bodies as previously described (Loh and Qualtiere, 1988).
When appropriate, the immunoprecipitates were digested
with Endoglycosidase F (Genzyme Corp.) overnight to
remove N-linked carbohydrates from the viral glycoproteins
using established protocols (Loh, 1991). The immunopre-
cipitated proteins were separated by SDS-PAGE (sodium
dodecyl sulfate-polyacrylamide gel electrophoresis) and
visualized by autoradiography.
Sequencing of the gp24 glycoprotein
To obtain enough protein for sequencing, 3T3-L1 cells
grown in four glass rolling bottles were infected with the
Vancouver strain of MCMV. Cells were scraped off the
bottle when virus production was at its peak, pelleted by
low-speed centrifugation, and solubilized in 45 mL of
immunoprecipitation buffer. The cell lysate was clarified bycentrifugation at 13,000 rpm for 45 min in a refrigerated
Beckman centrifuge and incubated with 50 AL of 6A1.21A-
containing ascitic fluid or normal mouse serum overnight at
4 8C. Then gp24 and its precursor 18.4-kDa glycoprotein
were precipitated by the addition of 100 AL of protein-L
agarose beads (Sigma Chemical Co., Canada), electro-
phoresed on a 12% SDS-polyacrylamide gel, and stained
with the Colloidal Blue staining kit (Invitrogen). The 18-
kDa band was excised from the lane containing the
6A1.21A immunoprecipitate and sent to the Harvard
University Microchemistry facility for sequence analysis.
A similar area of the gel from an adjacent lane containing
the normal mouse serum precipitate was also excised and
analyzed for comparative purposes. The glycoprotein was
digested with trypsin bin gelQ and sequence analysis was
performed at the Harvard facility by microcapillary reverse-
phase HPLC (high performance liquid chromatography)
nano-electrospray tandem mass spectrometry (ALC/MS/MS)
on a Finnigan LCQ DECA quadrupole ion trap mass
spectrometer. The fragmentation spectra were then corre-
lated with known sequences using the algorithm Sequest
developed at the University of Washington (Eng et al.,
1994) and programs developed in the Harvard laboratory
(Chittum et al., 1998).Acknowledgments
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